Effect of levocarnitine plus iron sucrose on nutritional status and life cycle in uremic patients with renal anemia.

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Li Ren, Jun Wu, Yanqin Shi, Dong Li, Gelu Huang, Nana Meng
{"title":"Effect of levocarnitine plus iron sucrose on nutritional status and life cycle in uremic patients with renal anemia.","authors":"Li Ren, Jun Wu, Yanqin Shi, Dong Li, Gelu Huang, Nana Meng","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Research team believes that Levocarnitine (L-carnitine) combined with Iron sucrose (IS) has a more significant positive effect on the nutritional status and lifespan of uremic patients with renal anemia and has carried out research and demonstration based on this. First, research team selected 90 uremic patients with renal anemia admitted to our hospital from February 2019 to February 2022 and randomized them to an experimental group (n=45) and a control group (n=45) that were given L-carnitine+IS and L-carnitine, respectively. The clinical efficacy and adverse reactions of the two groups of patients were counted and fasting venous blood was collected before and after treatment to test nutrient proteins, calcium and phosphorus metabolism and renal function. In addition, 1-year prognostic follow-up was performed to count the prognostic survival of the patients. The results of the study showed that the clinical efficacy of the experimental group was better than that of the control group and the nutritional protein, calcium and phosphorus metabolism and renal function were better after treatment (P<0.05), but there was no difference in the incidence of adverse reactions between the two groups (P>0.05). Prognostic follow-up showed that there was no difference in the prognostic overall survival rate between the two groups (P>0.05), but the median survival of the experimental group was prolonged compared with the control group (P<0.05). In conclusion, L-carnitine combined with IS effectively ameliorated the anemia status of patients, improved their nutritional status and prolonged their median survival.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"38 3","pages":"745-750"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Research team believes that Levocarnitine (L-carnitine) combined with Iron sucrose (IS) has a more significant positive effect on the nutritional status and lifespan of uremic patients with renal anemia and has carried out research and demonstration based on this. First, research team selected 90 uremic patients with renal anemia admitted to our hospital from February 2019 to February 2022 and randomized them to an experimental group (n=45) and a control group (n=45) that were given L-carnitine+IS and L-carnitine, respectively. The clinical efficacy and adverse reactions of the two groups of patients were counted and fasting venous blood was collected before and after treatment to test nutrient proteins, calcium and phosphorus metabolism and renal function. In addition, 1-year prognostic follow-up was performed to count the prognostic survival of the patients. The results of the study showed that the clinical efficacy of the experimental group was better than that of the control group and the nutritional protein, calcium and phosphorus metabolism and renal function were better after treatment (P<0.05), but there was no difference in the incidence of adverse reactions between the two groups (P>0.05). Prognostic follow-up showed that there was no difference in the prognostic overall survival rate between the two groups (P>0.05), but the median survival of the experimental group was prolonged compared with the control group (P<0.05). In conclusion, L-carnitine combined with IS effectively ameliorated the anemia status of patients, improved their nutritional status and prolonged their median survival.

左卡尼汀加蔗糖铁对尿毒症合并肾性贫血患者营养状况及生命周期的影响。
研究团队认为左卡尼汀(L-carnitine)联合蔗糖铁(IS)对尿毒症合并肾性贫血患者的营养状况和寿命有更显著的积极作用,并以此为基础进行了研究论证。首先,研究小组选择2019年2月至2022年2月在我院住院的尿毒症合并肾性贫血患者90例,随机分为实验组(n=45)和对照组(n=45),分别给予左旋肉碱+IS和左旋肉碱治疗。统计两组患者的临床疗效及不良反应,并于治疗前后采集空腹静脉血,检测营养蛋白、钙磷代谢及肾功能。并进行1年预后随访,统计患者预后生存期。研究结果显示,试验组临床疗效优于对照组,治疗后营养蛋白、钙磷代谢及肾功能均优于对照组(P0.05)。预后随访显示,两组患者预后总生存率差异无统计学意义(P < 0.05),但实验组中位生存期较对照组延长(P < 0.05)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
211
审稿时长
4.5 months
期刊介绍: Pakistan Journal of Pharmaceutical Sciences (PJPS) is a peer reviewed multi-disciplinary pharmaceutical sciences journal. The PJPS had its origin in 1988 from the Faculty of Pharmacy, University of Karachi as a biannual journal, frequency converted as quarterly in 2005, and now PJPS is being published as bi-monthly from January 2013. PJPS covers Biological, Pharmaceutical and Medicinal Research (Drug Delivery, Pharmacy Management, Molecular Biology, Biochemical, Pharmacology, Pharmacokinetics, Phytochemical, Bio-analytical, Therapeutics, Biotechnology and research on nano particles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信